Fate Therapeutics(FATE) - 2023 Q4 - Annual Results

Exhibit 99.1 Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initi ...